{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01297972",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CONEP 16119"
      },
      "Organization": {
        "OrgFullName": "University of Sao Paulo",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia",
      "OfficialTitle": "Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2014",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 2013",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 2013",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 16, 2011",
      "StudyFirstSubmitQCDate": "February 16, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 17, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 2, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 4, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Diego Villa Clé",
        "ResponsiblePartyInvestigatorTitle": "MD",
        "ResponsiblePartyInvestigatorAffiliation": "University of Sao Paulo"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Sao Paulo",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Mesenchymal stem cells have been tested in many autoimmune disorders with encouraging results and may be an alternative to the treatment of immune-mediated severe acquired aplastic anemia.",
      "DetailedDescription": "Acquired aplastic anemia is a bone marrow failure syndrome characterized by and empty bone marrow and low blood counts. Most of the cases are immune-mediated. Allogeneic bone marrow transplant is the preferable treatment modality for patients younger than 40 years with a matched sibling donor. Patients not eligible for transplant are treated with intensive immunosuppressive therapy often based on anti-thymocyte globulin and cyclosporine.\n\nHowever, up to one third of patients treated with immunosuppression are refractory and one third of those who response eventually relapse. Refractory and relapsed cases may be the result of insufficient immunosuppression and these cases may benefit from additional immunosuppression. Mesenchymal stem cells infusion may be a potential treatment option, considering its properties to modulate the immune system.\n\nRefractory or relapsed patients with aplastic anemia will be treated with conventional immunosuppressive regimen (anti-thymocyte globulin plus cyclosporine) combined with intravenous infusion of allogeneic unrelated bone marrow mesenchymal stem cells."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Aplastic Anemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Aplastic Anemia",
          "Mesenchymal Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Intravenous bone marrow mesenchymal stem cells infusion",
            "InterventionDescription": "After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added."
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.",
            "PrimaryOutcomeDescription": "Adverse events like allergic reactions,infectious diseases,organ dysfunction or other related to mesenchymal stem cells infusion will be assessed.",
            "PrimaryOutcomeTimeFrame": "After the mesenchymal stem cells infusion up to 6 mounth after"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Level of cytopenias",
            "SecondaryOutcomeTimeFrame": "weekly until 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Transfusional requirements",
            "SecondaryOutcomeDescription": "Units of blood or platelets transfused after the mesenchymal stem cells infusion will be measured and compared to previously.",
            "SecondaryOutcomeTimeFrame": "weekly until 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of infections and febrile neutropenia",
            "SecondaryOutcomeTimeFrame": "weekly until 6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of Acquired Aplastic Anemia\nRelapse/refractory to at least 1 immunosuppressive first line treatment\nNot eligible to allogeneic bone marrow transplantation\n\nExclusion Criteria:\n\nPrevious or current malignancy\nActive or latent infectious disease\nPositive serologic tests for HIV, HCV, HBV, HTLV-1 and 2, Syphilis or Chagas disease\nPrevious drug reaction for antithymocyte globulin, cyclosporin or corticosteroids\nSevere organic impairment (renal, hepatic, cardiac, pulmonary)\nUncontrolled hypertension or diabetes\nPregnancy\nPrevious history of allergic reaction to penicillin or streptomycin\nSevere psychiatric disorder",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Diego V Clé, MD",
            "OverallOfficialAffiliation": "University of São Paulo",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Rodrigo T Calado, MD",
            "OverallOfficialAffiliation": "University of São Paulo",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo",
            "LocationCity": "Ribeirão Preto",
            "LocationState": "São Paulo",
            "LocationZip": "14048900",
            "LocationCountry": "Brazil"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "16778145",
            "ReferenceType": "background",
            "ReferenceCitation": "Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006 Oct 15;108(8):2509-19. Epub 2006 Jun 15. Review."
          },
          {
            "ReferencePMID": "12592355",
            "ReferenceType": "background",
            "ReferenceCitation": "Fouillard L, Bensidhoum M, Bories D, Bonte H, Lopez M, Moseley AM, Smith A, Lesage S, Beaujean F, Thierry D, Gourmelon P, Najman A, Gorin NC. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia. 2003 Feb;17(2):474-6."
          },
          {
            "ReferencePMID": "26589752",
            "ReferenceType": "derived",
            "ReferenceCitation": "Clé DV, Santana-Lemos B, Tellechea MF, Prata KL, Orellana MD, Covas DT, Calado RT. Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia. Cytotherapy. 2015 Dec;17(12):1696-705. doi: 10.1016/j.jcyt.2015.09.006."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000740",
            "ConditionMeshTerm": "Anemia"
          },
          {
            "ConditionMeshId": "D000000741",
            "ConditionMeshTerm": "Anemia, Aplastic"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000080983",
            "ConditionAncestorTerm": "Bone Marrow Failure Disorders"
          },
          {
            "ConditionAncestorId": "D000001855",
            "ConditionAncestorTerm": "Bone Marrow Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3222",
            "ConditionBrowseLeafName": "Anemia",
            "ConditionBrowseLeafAsFound": "Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3223",
            "ConditionBrowseLeafName": "Anemia, Aplastic",
            "ConditionBrowseLeafAsFound": "Aplastic Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2241",
            "ConditionBrowseLeafName": "Bone Marrow Failure Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12270",
            "ConditionBrowseLeafName": "Pancytopenia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4286",
            "ConditionBrowseLeafName": "Bone Marrow Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T460",
            "ConditionBrowseLeafName": "Aplastic Anemia",
            "ConditionBrowseLeafAsFound": "Aplastic Anemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3431",
            "InterventionBrowseLeafName": "Antilymphocyte Serum",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M255749",
            "InterventionBrowseLeafName": "Thymoglobulin",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          }
        ]
      }
    }
  }
}